Tirzepatide: what to know about its use in type 2 diabetes and weight management
Let's talk frankly. Tirzepatide has been generating questions for a while. It's discussed in clinics, in the media, on social media, and in everyday conversations about diabetes, obesity, and weight loss.
What is tirzepatide and why is it considered different
Tirzepatide is an injectable medication administered weekly that acts on two receptors involved in metabolic regulation: GIP and GLP-1. Put simply, it doesn't just work on glucose, but also on mechanisms related to satiety, appetite, and energy utilisation. This dual action is one of the reasons it has garnered so much interest.
In the EU, its approved use includes adults with inadequately controlled type 2 diabetes and also adults with obesity, or with overweight accompanied by weight-related problems, always as part of an approach that includes diet and physical activity.
How it acts in the body and why it influences glucose and appetite
Tirzepatide improves glycaemic control by reducing fasting and post-meal glucose through various mechanisms. In addition, it increases the feeling of satiety, reduces hunger, and can decrease energy intake. It also delays gastric emptying, especially at the beginning, which influences the postprandial response and helps explain why many people report less appetite during treatment.
Explained without technical jargon: it can help the body better manage sugar and, at the same time, can make eating feel less impulsive or less voluminous. But that doesn't mean that the entire effect depends solely on the medication or that the result is identical in everyone.
Why there's so much talk about tirzepatide
There's so much talk about it because clinical studies have shown significant reductions in glycated haemoglobin and clinically significant weight loss, and because a higher percentage of treated patients achieved weight reduction targets of 5%, 10%, 15%, and even 20% compared to placebo.
It has also attracted attention because, compared to other previous approaches, it reinforces the idea that obesity and metabolic health are not well understood if reduced solely to "lack of willpower."
For whom it may be considered and what limitations should be clear
Tirzepatide is not intended for "anyone who wants to lose weight." Its suitability depends on specific clinical indications. In the EU, it is considered for inadequately controlled type 2 diabetes and for weight management in adults with obesity or with overweight accompanied by weight-related problems. Furthermore, it is a prescription-only medicine subject to monitoring.
Adverse effects and precautions that should not be minimised
One of the most common mistakes when a treatment becomes popular is to talk a lot about results and little about tolerability. In the case of tirzepatide, gastrointestinal adverse effects are common, especially at the beginning or during dose escalation. Among the most common are nausea, diarrhoea, vomiting, abdominal pain, and constipation.
There are also important warnings that should not be hidden in fine print. Cases of acute pancreatitis have been reported, and the risk of hypoglycaemia increases particularly when combined with insulin or sulfonylureas.
What to remember before considering this treatment
The useful question is not "does it work," nothing more. The useful question is another: if it is indicated in your case, with what objective, with what presentation, and within what follow-up plan.
You may also be interested in reading about semaglutide and GLP-1 injectables.
